Should I buy or sell Bausch Health Companies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks .

What is Bausch Health Companies' stock price target for 2024?

3 brokers have issued 12-month price objectives for Bausch Health Companies' stock. Their BHC share price targets range from $12.00 to $14.00. On average, they expect the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 51.0% from the stock's current price. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts .

How have BHC shares performed in 2024?

Bausch Health Companies' stock was trading at $8.02 at the start of the year. Since then, BHC shares have increased by 7.4% and is now trading at $8.61. View the best growth stocks for 2024 here .

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 22,500,000 shares, a decline of 5.4% from the March 15th total of 23,780,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is currently 8.5 days. Approximately 6.3% of the shares of the company are sold short. View Bausch Health Companies' Short Interest .

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BHC earnings forecast .

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion for the quarter, compared to analysts' expectations of $2.29 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 5,147.48% and a negative net margin of 6.76%. Bausch Health Companies's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.02 EPS.

What ETF holds Bausch Health Companies' stock?

LeaderShares Activist Leaders ETF holds 300,679 shares of BHC stock, representing 3.13% of its portfolio.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.3 billion-$9.3 billion, compared to the consensus revenue estimate of $9.0 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com . Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD) , Micron Technology (MU) , Constellation Software (CSU) , Intact Financial (IFC) , NVIDIA (NVDA) , Netflix (NFLX) , Alibaba Group (BABA) , Tesla (TSLA) , Advanced Micro Devices (AMD) and Bank of America (BAC) .

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different retail and institutional investors. Top institutional investors include Thompson Investment Management Inc. (0.06%), IMC Chicago LLC (0.00%), Range Financial Group LLC (0.02%), Marotta Asset Management (0.00%) and Salem Investment Counselors Inc. (0.00%). Insiders that own company stock include Amy B Wechsler , Christina Ackermann , Joseph F Gordon , Robert Spurr , Russell Barrans, Sam Eldessouky , Schutter Richard U De , Seana Carson and Steven D Miller . View institutional ownership trends .

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:BHC

Bausch Health Companies (BHC) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free BHC Stock Alerts

$8.61

-0.05 (-0.58%)

(As of 04/18/2024 ET)

Compare

Today's Range: $8.43
▼
$8.78
50-Day Range: $8.20
▼
$10.61
52-Week Range: $5.57
▼
$11.46

Volume: 2.18 million shs
Average Volume: 3.93 million shs
Market Capitalization: $3.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Get Bausch Health Companies alerts:

Bausch Health Companies MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 51.0% Upside
$13.00 Price Target
Short Interest: Healthy
6.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.42
Upright™ Environmental Score
News Sentiment: 0.66
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 3.04%
From $3.95 to $4.07 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

179th out of 918 stocks

Pharmaceutical Preparations Industry

70th out of 421 stocks

3.2

Analyst's Opinion

Consensus Rating
Bausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bausch Health Companies has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.31% of the float of Bausch Health Companies has been sold short.
Short Interest Ratio / Days to Cover
Bausch Health Companies has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Bausch Health Companies has recently decreased by 5.38%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bausch Health Companies does not currently pay a dividend.
Dividend Growth
Bausch Health Companies does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.
Environmental Sustainability
The Environmental Impact score for Bausch Health Companies is -1.42.

3.1

News and Social Media Coverage

News Sentiment
Bausch Health Companies has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Bausch Health Companies this week, compared to 4 articles on an average week.
Search Interest
42 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.12% of the stock of Bausch Health Companies is held by insiders.
Percentage Held by Institutions
78.65% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bausch Health Companies are expected to grow by 3.04% in the coming year, from $3.95 to $4.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bausch Health Companies is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bausch Health Companies is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Bausch Health Companies Stock (NYSE:BHC)

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

BHC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BHC Stock News Headlines

April 16, 2024 | americanbankingnews.com

Short Interest in Bausch Health Companies Inc. (NYSE:BHC) Declines By 5.4%

April 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

April 14, 2024 | americanbankingnews.com

Bausch Health Companies' (BHC) Sector Perform Rating Reaffirmed at Royal Bank of Canada

April 11, 2024 | reuters.com

Bausch wins US appeal to block Alvogen generic of diarrhea drug

April 9, 2024 | theglobeandmail.com

Closing Bell: Bausch Health Companies Inc down on Monday (BHC)

April 8, 2024 | msn.com

Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues

April 6, 2024 | msn.com

Bausch Health sues Amneal Pharma over Xifaxan generic

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

April 5, 2024 | finanznachrichten.de

Bausch Health Companies Inc.: Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

April 2, 2024 | finance.yahoo.com

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

March 30, 2024 | theglobeandmail.com

Bausch Health Companies: Stocks Overvalued by Analyst Consensus on TSX (BHC)

March 28, 2024 | insidermonkey.com

The Enduring Losses Incurred by Carl Icahn’s 10 Activist Targets over the Long Term

March 28, 2024 | msn.com

This Bausch Health Companies Unusually Active Option Is a No-Brainer

March 27, 2024 | businesswire.com

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

March 16, 2024 | finance.yahoo.com

BHC Mar 2024 9.000 call

March 16, 2024 | finance.yahoo.com

BHC Mar 2024 9.000 put

March 11, 2024 | finance.yahoo.com

BHC Mar 2024 5.500 call

March 6, 2024 | finance.yahoo.com

Bausch Health Companies Inc. (BHC)

March 6, 2024 | finanznachrichten.de

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

February 28, 2024 | businesswire.com

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

February 24, 2024 | seekingalpha.com

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

February 22, 2024 | marketwatch.com

Bausch Health 4Q Loss Narrows, Revenue Growth Tops Analysts

February 21, 2024 | msn.com

Bausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed Views

February 21, 2024 | msn.com

Bausch Health Companies Q4 2023 Earnings Preview

February 21, 2024 | finance.yahoo.com

Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics

February 21, 2024 | businesswire.com

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

See More Headlines

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:BHC
CUSIP: N/A
CIK: 885590
Web: www.bauschhealth.com
Phone: (514) 744-6792
Fax: 514-744-6272
Employees: 20,270
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.00
High Stock Price Target: $14.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +51.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 2.18
P/E Growth: N/A
Net Income: $-592,000,000.00
Net Margins: -6.76%
Pretax Margin: -4.45%
Return on Equity: 5,147.48%
Return on Assets: 4.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.30
Quick Ratio: 0.94

Sales & Book Value

Annual Sales: $8.76 billion
Price / Sales: 0.36
Cash Flow: $7.12 per share
Price / Cash Flow: 1.21
Book Value: ($0.23) per share
Price / Book: -37.43

Miscellaneous

Outstanding Shares: 365,410,000
Free Float: 335,741,000
Market Cap: $3.15 billion
Optionable: Optionable
Beta: 0.85

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Thomas J. Appio (Age 62)
CEO & Director
Comp: $2.74M
Mr. John S. Barresi (Age 51)
Senior VP, Controller, Chief Accounting Officer & Interim CFO
Comp: $796.8k
Ms. Seana Carson (Age 51)
Executive VP & General Counsel
Comp: $872.65k
Mr. Mirza Dautbegovic
Senior VP & COO
Mr. Josh Coyle
Senior Vice President of Sales & Salix
Ms. Kathleen Fitzpatrick
Senior VP & Chief HR Officer
Dr. Tage Ramakrishna M.D. (Age 50)
Chief Medical Officer and President of R&D
Mr. Jeff Hartness
Executive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs
Dr. Graham Jackson
Senior VP & Chief Quality Officer
Mr. Cees Heiman
Senior Vice President of Europe & Canada

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BHC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings or view top-rated stocks.
What is Bausch Health Companies' stock price target for 2024?: 3 brokers have issued 12-month price objectives for Bausch Health Companies' stock. Their BHC share price targets range from $12.00 to $14.00. On average, they expect the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 51.0% from the stock's current price.
View analysts price targets for BHC or view top-rated stocks among Wall Street analysts.
How have BHC shares performed in 2024?: Bausch Health Companies' stock was trading at $8.02 at the start of the year. Since then, BHC shares have increased by 7.4% and is now trading at $8.61.
View the best growth stocks for 2024 here.
Are investors shorting Bausch Health Companies?: Bausch Health Companies saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 22,500,000 shares, a decline of 5.4% from the March 15th total of 23,780,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is currently 8.5 days. Approximately 6.3% of the shares of the company are sold short.
View Bausch Health Companies' Short Interest.
When is Bausch Health Companies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BHC earnings forecast.
How were Bausch Health Companies' earnings last quarter?: Bausch Health Companies Inc. (NYSE:BHC) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion for the quarter, compared to analysts' expectations of $2.29 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 5,147.48% and a negative net margin of 6.76%. Bausch Health Companies's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.02 EPS.

What ETF holds Bausch Health Companies' stock?: LeaderShares Activist Leaders ETF holds 300,679 shares of BHC stock, representing 3.13% of its portfolio.
What guidance has Bausch Health Companies issued on next quarter's earnings?: Bausch Health Companies issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.3 billion-$9.3 billion, compared to the consensus revenue estimate of $9.0 billion.
What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?: 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Bausch Health Companies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).
Who are Bausch Health Companies' major shareholders?: Bausch Health Companies' stock is owned by many different retail and institutional investors. Top institutional investors include Thompson Investment Management Inc. (0.06%), IMC Chicago LLC (0.00%), Range Financial Group LLC (0.02%), Marotta Asset Management (0.00%) and Salem Investment Counselors Inc. (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson and Steven D Miller.
View institutional ownership trends.
How do I buy shares of Bausch Health Companies?: Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial